Physician profile
Ryan Koch
NPI 1386684603
$15,295.93
in general payments reported to CMS, 2019-2025
66 companies · $2,189 in 2025
The $2,189 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,430 · 2020: $1,075 · 2021: $2,633 · 2022: $1,942 · 2023: $2,262 · 2024: $2,764 · 2025: $2,189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,884 · Education: $332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,884.45 |
| Education | $331.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,305.40 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,168.57 | 2019-2025 | Lynparza, Tagrisso, Imfinzi |
| Pfizer INC. | $1,063.14 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $973.67 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Incyte Corporation | $732.31 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Seagen INC. | $596.08 | 2019-2025 | Adcetris |
| Glaxosmithkline, LLC. | $554.81 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Genentech USA, INC. | $531.21 | 2019-2025 | Tecentriq, Polivy, Lunsumio |
| Lilly USA, LLC | $522.30 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Daiichi Sankyo INC. | $511.48 | 2019-2025 | Enhertu, Injectafer, Vanflyta |
| Celgene Corporation | $479.49 | 2019-2025 | Reblozyl, Opdualag |
| Genzyme Corporation | $464.70 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $453.71 | 2019-2025 | Opdivo, Opdualag |
| Myriad Genetic Laboratories, INC. | $450.70 | 2023-2025 | Myrisk |
| Janssen Biotech, INC. | $406.26 | 2019-2025 | Darzalex, Tecvayli, Erleada |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Koch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.